Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Sciences and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bio-Rad Laboratories reports robust earnings, eyes growth through new products

Bio-Rad Laboratories showcased strong financial performance, operational improvements, and strategic initiatives during the Q4 2022 earnings call. Despite challenges like supply chain disruptions and margin impacts, the company remains optimistic about its growth prospects and commitment to long-term targets.

Bio-Rad reports resilient Q1 performance amidst challenges and opportunities

Bio-Rad Laboratories navigated challenges in Q1 2023 to achieve core sales growth and solid non-GAAP net income, with a revised 2023 outlook projecting 4.5% revenue growth.
The impact of Russian sanctions and margin improvement plans were key discussion points, alongside the company's focus on expense management and operational transformation.
With a strategic approach to growth, strong performance in key business segments, and a focus on operational efficiency, Bio-Rad aims to capitalize on opportunities for expansion and resilience.

Bio-Rad reports Q2 earnings decline, eyes ddPCR growth opportunities

Bio-Rad Laboratories faced challenges in BioPharma but showed strengths in Clinical Diagnostics and Life Science segments.
Despite a decline in net sales, the company reported strong demand for ddPCR and authorized a new share repurchase program.
Anticipated challenges in BioPharma and China may impact revenue growth, but opportunities exist in expanding ddPCR sales and cost-saving measures.
The company maintains a strong cash position, views its valuation favorably, and plans to participate in upcoming healthcare conferences.

Bio-Rad Labs faces Q3 challenges, eyes ddPCR market growth

Bio-Rad Laboratories faced challenges in Q3 2023 due to biopharma segment issues and economic constraints in China, impacting revenue and forecasting.
Despite weaknesses, the company saw growth in Clinical Diagnostics revenue and remains focused on operational transformation and strategy execution.
Analysts raised concerns about market dynamics and share losses, while Bio-Rad plans to address challenges and capitalize on opportunities in the ddPCR market.
The company anticipates a strong Q4 to offset Q3 challenges and is prepared for potential macroeconomic impacts on biotechnology spending.

Bio-Rad Labs reports Q4 revenue decline, eyes growth opportunities

Bio-Rad Laboratories navigated challenges in Q4 2023, with revenue declines but operational resilience in key segments.
The company faces headwinds in the China market but sees opportunities in new product launches and market recovery.
Financial stability is evident with strong cash reserves, while strategic adjustments are needed to drive future growth.
Guidance for 2024 hints at a potential turnaround, with a focus on operational efficiency and revenue expansion.

Bio-Rad Laboratories reports mixed Q1 performance, maintains outlook optimism

Bio-Rad Laboratories' Q1 2024 earnings call highlighted a mixed performance with declines in Life Science sales but growth in Clinical Diagnostics. Despite challenges in certain segments, the company maintains its full-year outlook and is optimistic about long-term growth strategies and market trends.

Bio-Rad Laboratories reports solid Q2 performance amidst global spending constraints

Bio-Rad Laboratories had a solid quarter but revised full-year outlook due to global spending constraints.
Operational improvements and successful share repurchases demonstrate resilience and strategic focus.
Challenges in the Life Science group highlight areas for improvement and strategic decision-making.

Bio-Rad Laboratories exceeds revenue targets in Q3 2024 earnings call

Bio-Rad Laboratories reported a strong Q3 performance with revenue surpassing targets driven by product mix and cost efficiencies.
While facing challenges in certain segments, opportunities lie in the expected return to growth in 2025 and the expansion of the Droplet Digital PCR franchise.
Maintained revenue guidance for 2024 with margin improvements and a focus on corporate transformations and acquisitions for future growth.
Analyst questions during the call covered a range of topics including margins, market dynamics, and product pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, and test kits. The company was founded by David S. Schwartz and Alice N. Schwartz in 1952 and is headquartered in Hercules, CA.

Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q4 2019 Results - Earnings Call Transcript

Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bio-Rad Laboratories (BIO) Reports Next Week: Wall Street Expects Earnings Growth

Bio-Rad's (BIO) new product uptake in the United States is appreciative with the recent 510(k) clearance of the IH-Reader 24.

Bio-Rad Gains on New Product Portfolio Despite Currency Woes

Bio-Rad Will Grow In 2020 But Won't Match This Year's Stock Price Gains

Bio-Rad's (BIO) new product acceptance in the United States is a positive with the recent 510(k) clearance of the IH-Reader 24.

Bio-Rad's Blood Typing Market Growth Strong on New Products

Growing strength in many of Bio-Rad's (Bio) key product lines across major geographic regions buoys investors' optimism on the stock.

Bio-Rad (Bio) Q3 Earnings Beat Estimates on All-Line Growth

The healthcare stock is smoking hot this year. But it's Q3 results were more lukewarm.

Bio-Rad's Q3 Results: Some Good News and Some Bad News

Bio Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q3 2019 Results - Earnings Call Transcript

Bio-Rad (BIO) delivered earnings and revenue surprises of 18.38% and -0.14%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Bio-Rad Laboratories (BIO) Q3 Earnings Beat Estimates

Domino's Pizza

National Retail Properties

Paycom Software

Zebra Technologies

If you're looking for real long term growth, then mid-cap stocks have to be on your menu. Here are 5 that are some of the best examples of what the market segment has to offer.

5 Stocks to Buy in the Mighty Middle

Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock?

Bio-Rad (BIO) Up 8.8% Since Last Earnings Report: Can It Continue?

Perrigo

PRGO vs. BIO: Which Stock Is the Better Value Option?

Bio-Rad will benefit from purchased and home-developed technologies approved by FDA.

Bio-Rad Laboratories Is Poised For Long-Term Growth

We are upbeat about Bio-Rad's (BIO) year-over-year revenue growth within the Clinical Diagnostics segment in Q2.

Bio-Rad (Bio) Q2 Earnings Beat Estimates, Margins Expand

Bio Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q2 2019 Results - Earnings Call Transcript

Becton, Dickinson and Co.

Thermo Fisher Scientific

In-vitro Diagnostics has successfully proven itself to be the best diagnostic procedures. So, investors can add stocks from this space to their watchlist.

IVD Market Sustains Momentum: 3 Stocks in Focus

Abbott Labs

Abbott (ABT) scores higher than Bio-Rad (BIO) in terms of valuation and one-year price performance.

ABT or BIO: Which Stock Has Better Potential Right Now?

I like the look of Bio-Rad. Q119 EPS of $1.65 beat expectations by $0.5. GAAP EPS of $28.74 gives a P/E ratio of 10.8 - very low for the sector.

Bio-Rad Laboratories: More Growth Ahead

Bio-Rad (BIO) witnesses revenue growth at the Life Sciences segment in Q1 on strength in cell biology, droplet Digital PCR and other product lines.

Bio-Rad (BIO) Q1 Earnings Beat Estimates, Margins Expand

Bio-Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q1 2019 Results - Earnings Call Transcript

Within the Life Sciences segment, high investment in several geographies along with product launches and new technologies is resulting in a strong upside for Bio-Rad (BIO).

Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings?

The regulatory go-ahead is in line with Bio-Rad's (BIO) strategy of strengthening in the transfusion medicine market of the United States.

Bio-Rad's IH-500 System Secures 510(K) From the FDA

The recent development will help Bio-Rad rake in increased top-line contributions from the Clinical Diagnostics business.

Bio-Rad's Latest FDA Nod to Boost Clinical Diagnostics Arm

Why Is Bio-Rad (BIO) Up 12.8% Since Last Earnings Report?

Bio-Rad (BIO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

News for Bio-Rad Laboratories Stock (BIO)